RSS feedCSL
’Vaccines give a boost to pharma M&A
A recent flurry of deals in the pharmaceutical sector highlights what savvy investors have known for some time — vaccines are the new M&A targets.
The Wall Street Journal notes on Monday that the recent health scares over global pandemics and the growing involvement of governments in purchasing vaccines en masse have become key driving forces in the thriving world of pharma M&A.
CSL scraps Talecris deal
CSL ended its proposed $3.1bn acquisition of Talecris Biotherapeutics after the deal was blocked by the US Federal Trade Commission and said it will use some of the cash to buy back its shares, reports Bloomberg. CSL,
US blocks CSL’s $3bn Talecris bid
The US Federal Trade Commission authorised a lawsuit on Wednesday to block the proposed $3.1bn acquisition of Talecris, a US plasma provider, by Australia’s CSL, citing concerns over US antitrust laws.
CSL says US may block Talecris deal
CSL, Australian blood plasma products maker, said that US regulators are likely to block its planned $3.1bn takeover of US rival Talecris Biotherapeutics. US regulators had indicated they would oppose the deal – agreed last August – although a formal decision was still a few days away,
China South Loco dazzles on debut
China South Locomotive & Rolling Stock made one of this year’s most successful Chinese stock debuts on Monday with its shares jumping up to 83% despite the broader Shanghai market falling to a 19-month low.
Australia’s CSL to buy Talecris for $3.1bn
CSL, the world’s second-largest maker of specialised blood transfusion products, agreed to buy Talecris Biotherapeutics of the US for $3.1bn cash, boosting sales by more than a third with its biggest acquisition,